Early Experience With Neovasc’s Mitral Valve Is Encouraging; Edwards’ Disappoints
This article was originally published in The Gray Sheet
Executive Summary
Physicians attending the EuroPCR conference in Paris heard presentations of first-in-man case studies on two new transcatheter mitral valve replacement technologies, one from Neovasc, and one from Edwards Lifesciences.
You may also be interested in...
Neovasc Sees Opportunities In Refractory Angina And Mitral Regurgitation Markets
Neovasc Inc. is targeting two highly underserved markets in cardiology – refractory angina and mitral valve disease – with unique transcatheter solutions. The angina device, called the Neovasc Reducer, is expected to enter the European market early next year.
FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials
Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.
Keeping Track: Return & Renewal At US FDA
Takeda’s TAK-721 is back, ARS Pharma will be back soon to appeal neffy complete response letter, US FDA’s Project Renewal brings Temodar labeling in current day, and more highlights from the Pink Sheet’s US FDA Performance Tracker.